Tilray Brands (TLRY) Income from Continuing Operations (2017 - 2026)

Tilray Brands (TLRY) posted Income from Continuing Operations of 25233000.0 for Q1 2026, up 42.01% on a QoQ basis from 43509000.0 in Q4 2025, and up 96.82% year-over-year from 12820332.12 in Q1 2025.

Tilray Brands (TLRY) Income from Continuing Operations (2017 - 2026) Analysis & Trends

Tilray Brands' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 25233000.0 for Q1 2026.

  • Quarterly Income from Continuing Operations rose 96.82% year-over-year to 25233000.0 in Q1 2026, while the trailing twelve-month figure through Feb 2026 was 1460635000.0 (down 72.77% YoY) and the FY2025 annual result came in at 2306867000.0, down 1559.72% from the prior year.
  • Income from Continuing Operations was 25233000.0 for Q1 2026 at Tilray Brands, up from 43509000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 816311000.0 in Q2 2023 and bottomed at 1393406000.0 in Q2 2025.
  • A 5-year average of 190690058.82 and a median of 55863000.0 in 2023 frame the typical range for Income from Continuing Operations.
  • Peak annual rise in Income from Continuing Operations reached 425.45% in 2023, while the deepest fall reached 2378.71% in 2023.
  • Tilray Brands' Income from Continuing Operations stood at 85061000.0 in 2022, then soared by 45.71% to 46183000.0 in 2023, then tumbled by 84.65% to 85275000.0 in 2024, then soared by 48.98% to 43509000.0 in 2025, then surged by 42.01% to 25233000.0 in 2026.
  • Business Quant data shows TLRY's Income from Continuing Operations at 25233000.0 in Q1 2026, 43509000.0 in Q4 2025, and 1513000.0 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 370.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn -3.58 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 274.90 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 57.00 Mn
10 Tilray Brands 465.02 Mn 373.06 Mn 54.95 Mn -25.23 Mn

Historic Data

Download Data
DateValue
Feb 28, 2026 -25.23 Mn
Nov 30, 2025 -43.51 Mn
Aug 31, 2025 1.51 Mn
May 31, 2025 -1.39 Bn
Feb 28, 2025 -793.53 Mn
Nov 30, 2024 -85.28 Mn
Aug 31, 2024 -34.65 Mn
May 31, 2024 68.04 Mn
Feb 29, 2024 -104.98 Mn
Nov 30, 2023 -46.18 Mn
Aug 31, 2023 -55.86 Mn
May 31, 2023 816.31 Mn
Feb 28, 2023 -1.20 Bn
Nov 30, 2022 -85.06 Mn
Aug 31, 2022 -65.79 Mn
May 31, 2022 -250.82 Mn
Feb 28, 2022 52.48 Mn
Nov 30, 2021 5.80 Mn
Aug 31, 2021 -34.60 Mn
May 31, 2021 345.90 Mn